New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2014
10:00 EDTARIA, VNO, MSO, IZEA, FST, NEM, SEAC, ITMN, SUNS, DWA, VLRS, VLP, FMS, HUM, JAZZ, JNPR, NIHD, PSXP, SWY, TOL, BOOM, DRHOn The Fly: Analyst Downgrade Summary
DiamondRock (DRH) downgraded to Neutral from Buy at ISI Group... Dynamic Materials (BOOM) downgraded to Neutral from Overweight at JPMorgan... Fresenius Medical (FMS) downgraded to Neutral from Buy at UBS... Humana (HUM) downgraded to Sell from Neutral at Citigroup... Jazz Pharmaceuticals (JAZZ) downgraded to Hold from Buy at Cantor... Juniper (JNPR) downgraded to Neutral from Overweight at Piper Jaffray... NII Holdings (NIHD) downgraded to Neutral from Outperform at Macquarie... Phillips 66 Partners (PSXP) downgraded to Neutral from Outperform at Credit Suisse... Safeway (SWY) downgraded to Neutral from Overweight at JPMorgan... Toll Brothers (TOL) downgraded to Market Perform from Outperform at Keefe Bruyette... Valero Energy Partners (VLP) downgraded to Neutral from Outperform at Credit Suisse... Volaris (VLRS) downgraded to Hold from Buy at Deutsche Bank... Vornado (VNO) downgraded to In-Line from Outperform at Imperial Capital... Martha Stewart (MSO) downgraded to Hold from Buy at Noble Financial... IZEA (IZEA) downgraded to Neutral from Buy at Merriman... Forest Oil (FST) downgraded to Market Perform from Outperform at Wells Fargo... Newmont Mining (NEM) downgraded to Hold from Buy at Argus... SeaChange (SEAC) downgraded to Neutral from Buy at Dougherty... InterMune (ITMN) downgraded to Market Perform from Outperform at Leerink... Solar Senior Capital (SUNS) downgraded to Hold from Buy at BB&T... DreamWorks Animation (DWA) downgraded to Underweight from Neutral at Piper Jaffray... ARIAD (ARIA) downgraded to Neutral from Buy at Chardan.
News For DRH;BOOM;FMS;HUM;JAZZ;JNPR;NIHD;PSXP;SWY;TOL;VLP;VLRS;VNO;MSO;IZEA;FST;NEM;SEAC;ITMN;SUNS;DWA;ARIA From The Last 14 Days
Check below for free stories on DRH;BOOM;FMS;HUM;JAZZ;JNPR;NIHD;PSXP;SWY;TOL;VLP;VLRS;VNO;MSO;IZEA;FST;NEM;SEAC;ITMN;SUNS;DWA;ARIA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
July 22, 2014
10:43 EDTHUMAppeals court bars subsidies in health care law
A three-judge panel of the D.C. Circuit Court of Appeals struck down part of President Obama's healthcare law by siding today with plaintiffs who argued that the law barred the government from giving subsidies to people in states that chose not to set up their own insurance marketplaces. The appeals court stated, "Because we conclude that the ACA unambiguously restricts the section 36B subsidy to insurance purchased on Exchanges 'established by the State,' we reverse the district court and vacate the IRS’s regulation." Twenty-seven states decided against setting up marketplaces, and another nine states partially opted out, according to the Washington Post.
July 21, 2014
11:19 EDTITMNInterMune July weekly volatility elevated
Subscribe for More Information
10:33 EDTDWADreamWorks Animation downgraded to Hold from Buy at Ascendiant
10:31 EDTNIHDHigh option volume stocks:
High option volume stocks: EZPW LCI STLD SIAL FL OREX CROX NIHD EXTR BBT
July 20, 2014
12:53 EDTJNPRJuniper shares could rise over 30%, Barron's says
Subscribe for More Information
July 18, 2014
15:18 EDTNEMGoldcorp showed interest in Newmont Ghana mines, Bloomberg says
Goldcorp (GG) showed interest in potentially buying gold mines in Africa from Newmont Mining (NEM) while the latter was in merger talks with Barrick Gold (ABX) earlier this year, said Bloomberg, citing people familiar with the situation. Reference Link
14:53 EDTNEMGoldcorp showed interest in Newmont Mining assets in Africa, Bloomberg says
Subscribe for More Information
July 17, 2014
12:42 EDTITMNInterMune receives FDA Breakthrough Therapy Designation for pirfenidone
InterMune announced that pirfenidone has been granted Breakthrough Therapy Designation from the U.S. FDA. This designation is reserved for drugs that are intended to treat a serious or life threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. Pirfenidone is an investigational treatment for adult patients with idiopathic pulmonary fibrosis.
10:00 EDTJAZZOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:00 EDTFMSFresenius Medical shares should be bought, says Bernstein
Bernstein notes that Fresenius' (FMS) stock has sharply underperformed versus its competitor, DaVita (DVA), since May 2012. But the firm predicts that Fresenius' core U.S. business should outperform that of DaVita going forward. Bernstein adds that it finds Fresenius' business units aside from its U.S. dialysis clinics more attractive than DaVita's businesses other than its U.S. dialysis clinics.
July 16, 2014
17:22 EDTJAZZJazz Pharmaceuticals initiated with a Neutral at SunTrust
Subscribe for More Information
July 15, 2014
10:40 EDTVLPValero Energy Partners increases Q2 distribution by 5% to 22.25c
Subscribe for More Information
07:15 EDTSWYIIR Holdings to hold a conference
14th Annual Shopper Insights in Action Conference to be held in Chicago on July 14-16.
July 14, 2014
16:15 EDTHUMHumana, Tenet sign new multi-year national agreement
Subscribe for More Information
10:00 EDTDWAOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:29 EDTSEACSeaChange management to meet with Brean Capital
Subscribe for More Information
07:37 EDTARIAARIAD announces continuation of Iclusig review under Article 20 procedure
ARIAD Pharmaceuticals announced that the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency has provided the company with a request for limited additional information regarding Iclusig as part of its ongoing review under the Article 20 referral procedure. The PRAC has requested further information regarding proposed dose modifications after achievement of a response and patient monitoring and details concerning a risk management plan. Following ARIAD’s response and input from the agency’s Scientific Advisory Group, the company expects that the PRAC will complete its review and make final recommendations to the Committee for Medicinal Products for Human Use at its meeting in October. As we finalize our recommendations on dose modifications of Iclusig and response monitoring of patients, we will work closely with the European regulatory agency and its expert advisors so that CML patients and their treating physicians have the best guidance available supporting the appropriate use of Iclusig,” said Timothy P. Clackson, Ph.D., president of research and development and chief scientific officer at ARIAD. In March ARIAD submitted responses to initial questions outlined by the PRAC as part of the Article 20 process, which was initiated in December of last year, and responses to a second set of questions were submitted to the PRAC in June.
07:22 EDTHUMHealthcare Education Associates to hold a conference
4th Annual RISE California Summit to be held in San Diego on July 13-15.
06:54 EDTDWADreamWorks Animation downgraded at B. Riley
Subscribe for More Information
06:18 EDTDWADreamWorks Animation downgraded to Neutral from Buy at B. Riley
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use